Health Care & Life Sciences » Pharmaceuticals | Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
7,150.00
8,250.00
28,895.00
20,383.00
4,484.00
44,509
SG&A Expense
92,348.00
87,838.00
79,199.00
83,413.00
83,635.00
116,311
EBIT
87,790.00
91,249.00
51,743.00
63,971.00
79,616.00
72,683
Unusual Expense
1,679.00
-
-
5,770.00
-
-
Non Operating Income/Expense
-
98.00
57.00
88.00
732.00
-
Pretax Income
89,027.00
90,908.00
51,464.00
69,216.00
77,992.00
70,480
Consolidated Net Income
89,027.00
90,908.00
51,464.00
69,216.00
77,992.00
70,480
Net Income
89,027.00
90,908.00
51,464.00
69,216.00
77,992.00
70,480
Net Income After Extraordinaries
89,027.00
90,908.00
51,464.00
69,216.00
77,992.00
70,480
Net Income Available to Common
89,027.00
90,908.00
51,464.00
69,216.00
77,992.00
70,480
EPS (Basic)
1.02
1.04
0.58
0.73
0.62
0.44
Basic Shares Outstanding
87,288.00
87,662.00
88,434.00
94,387.00
126,324.00
160,529
EPS (Diluted)
1.02
1.04
0.58
0.73
0.62
0.44
Diluted Shares Outstanding
87,288.00
87,662.00
88,434.00
94,387.00
126,324.00
160,529
EBITDA
85,198.00
88,890.00
50,304.00
63,030.00
79,151.00
72,089
Other Operating Expense
-
9,302.00
-
-
-
-
Non-Operating Interest Income
442.00
243.00
222.00
437.00
892.00
2,203

About Rigel Pharmaceuticals

View Profile
Address
1180 Veterans Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.rigel.com
Updated 07/08/2019
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. It focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.